Prostate Cancer-Associated Diagnostic Marker-1 (PCADM-1) is produced only by prostate cancer cells, is detected in high levels in the urine of prostate cancer patients and can be used as a highly specific marker for the detection of prostate cancer. CADM-1 is the mutated form of a ribosomal protein (RPS2) produced only by tumor cells and thus can be utilized as a highly specific marker for prostate cancer.

Ongoing research has indicated this that PCADM-1 is highly expressed by prostate cancer cells lacking the androgen receptor (AR). Since the AR directly regulates the synthesis of PSA, AR-negative cancer cells cannot be identified and monitored by measuring PSA, a limitation that can be circumvented by testing for PCADM-1.